The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 7.7 Billion in 2023. Looking forward, the market is projected to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.66% during 2023-2032.
Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart’s capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs.
It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.
The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure.
This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.
2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2024-2032?
3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?
Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart’s capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs.
It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.
The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure.
This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on drug class, route of administration and end user.Breakup by Drug Class:
- Endothelin Receptor Antagonists (ERAs)
- Vasodilators
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Calcium Channel Blockers (CCBs)
- Prostacyclin and Prostacyclin Analogs
- Others
Breakup by Route of Administration:
- Inhalation
- Injectable
- Oral Administration
Breakup by End User:
- Hospitals
- Clinics
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.Key Questions Answered in This Report
1. What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2023?2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2024-2032?
3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Route of Administration
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Actelion Pharmaceuticals Ltd (Johnson & Johnson)
- Arena Pharmaceuticals Inc.
- AstraZeneca PLC
- Bayer Aktiengesellschaft
- Daiichi Sankyo Company Limited
- Gilead Science Inc.
- GlaxoSmithKline PLC
- Merck KGaA
- Novartis International AG
- Pfizer Inc.
- United Therapeutics Corporation
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 7.7 Billion |
| Forecasted Market Value ( USD | $ 11.6 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
